Encorafenib
Tier C — Watch / tradeEncorafenib · all drugs expiring in 2030 →
Targets：B-raf
Brand：BRAFTOVI, Braftovi
Indications (approved)：Non-small cell lung cancer, Colorectal cancer, Thyroid cancer, Melanoma
Regional status
Synthetic routes & intermediates1 routes
Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.
| Code | CAS No. | Intermediate |
|---|---|---|
| ENCO-001 | 100-52-7Available | benzaldehyde |
| ENCO-002 | 16726-41-3 | isopropylhydrazine hydrochloride |
| ENCO-003 | 1086271-92-2 | (E)-1-benzylidene-2-isopropylhydrazine |
| ENCO-004 | 123-06-8 | 2-(ethoxymethylene)malononitrile |
| ENCO-005 | 1086250-41-0 | (E)-2-((2-benzylidene-1-isopropylhydrazinyl)methylene)malononitrile |
| ENCO-006 | 89897-29-0 | 3-amino-1-isopropyl-1H-pyrazole-4-carbonitrile |
| ENCO-007 | 1269440-48-3 | 1-(3-amino-1-isopropyl-1H-pyrazol-4-yl)ethan-1-one |
| ENCO-008 | 1269440-49-4 | 1-(3-iodo-1-isopropyl-1H-pyrazol-4-yl)ethan-1-one |
| ENCO-009 | 1269440-51-8 | (Z)-3-(dimethylamino)-1-(3-iodo-1-isopropyl-1H-pyrazol-4-yl)prop-2-en-1-one |
| ENCO-010 | 50-01-1 | guanidine hydrochloride |
| ENCO-011 | 1269440-54-1 | 4-(3-iodo-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-amine |
| ENCO-012 | 1269440-57-4 | 4-(3-iodo-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-ol |
| ENCO-013 | 1269440-58-5 | 2-chloro-4-(3-iodo-1-isopropyl-1H-pyrazol-4-yl)pyrimidine |
| ENCO-014 | 1229025-32-4 | methyl (S)-(1-aminopropan-2-yl)carbamate hydrochloride |
| ENCO-015 | 1269440-60-9 | methyl (S)-(1-((4-(3-iodo-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate |
| ENCO-016 | 1269440-69-8 | tert-butyl (5-chloro-2-fluoro-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)carbamate |
| ENCO-017 | 1269440-77-8 | methyl (S)-(1-((4-(3-(3-((tert-butoxycarbonyl)amino)-5-chloro-2-fluorophenyl)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate |
| ENCO-018 | 1269440-78-9 | methyl (S)-(1-((4-(3-(3-amino-5-chloro-2-fluorophenyl)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate |
| ENCO-019 | 1269440-99-4 | methyl (S)-(1-((4-(3-(5-chloro-2-fluoro-3-(N-(methylsulfonyl)methylsulfonamido)phenyl)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate |
| ENCO-020 | 1996-30-1 | 2-bromo-4-chloro-1-fluorobenzene |
| ENCO-021 | 1269232-93-0 | 3-bromo-5-chloro-2-fluorobenzoic acid |
| ENCO-022 | 1269232-94-1 | tert-butyl (3-bromo-5-chloro-2-fluorophenyl)carbamate |
| ENCO-023 | 73183-34-3Available | 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane) |
Frequently asked questions
What are the approved indications of Encorafenib?
Approved indications include: Non-small cell lung cancer, Colorectal cancer, Thyroid cancer, Melanoma.
When does the Encorafenib patent expire?
Based on public sources, the Encorafenib patent expires in 2030.
How many synthesis routes are recorded for Encorafenib?
1 synthesis routes are recorded; the shortest is 17 steps with / total yield. Intermediates in each route carry codes and CAS numbers.
Where can I buy Encorafenib intermediates?
2 intermediate CAS of Encorafenib are available through the Unibest supply network — see the route tables on this page and request a quote per CAS.
How do I get a quote for Encorafenib intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-29